ViRexx Medical Corp. (TSX:VIR)(AMEX: REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B and C and embolotherapy treatments for tumors, announced today that following a positive meeting with the U.S. Department of Defense at “The Capitol Hill BioDefense Advisory Showcase & Roundtable” in January 2006, ViRexx has successfully recruited procurement advocate Frank Rapoport of McKenna Long & Aldridge. Mr. Rapoport will pursue acquisitions of development contracts from the U.S. Department of Defense and NIH with a particular focus on the potential of the Chimigen™ technology in addressing BioDefense and pandemic threats. Frank Rapoport has successfully negotiated over $1 billion dollars in contracts from the U.S. Government, working with a variety of large vaccine and pharmaceuticals as well as biotechnology companies.
